FrontMIND data interesting (Lenz et al) • tafa-len-RCHOP v RCHOP IPI3-5 LBCL • 3y PFS ⬆️ 6-7% • higher in centrally r/v DLBCL • no signif OS • more tox: haem & GI • no COO difference • tafa weekly for all 6 cycles Does benefit overcome tox & logistic impact. #EHA2026

Townsend - real world bispecific antibody UK data, 3L DLBCL • whole cohort 40% ORR and 24% CMR • in trial eligible pts, CMR > 40% which is encouraging. • pt selection crucial - better with lower PS & if receive 2 cycles • PFS worse if prior benda < 6mo #EHA2026

Many congratulations to @ABarrettHaem for delivering a fantastic presentation in the final data of the Avenue trial - avelumab prior to a RATHL approach in Hodgkin. #EHA2026

bbc.co.uk/news/articles/c4gy… BBC Piece on UCL CAR-T programme for autoimmune diseases! Well done @drclaireroddie @haem

CONGRESS | #EHA2026 | PRESENTATION Matthew R. Wilson, Beatson West of Scotland Cancer Centre, Glasgow, presents findings from an international retrospective analysis evaluating HD-MTX for CNS relapse prophylaxis in patients with ultra high-risk LBCL receiving curative-intent chemoimmunotherapy (N = 1,923; HD-MTX, n = 872; no HD-MTX, n = 1,051). HD-MTX did not significantly reduce 3-year CNS relapse vs no HD-MTX in UHR patients (6.6% vs 6.7%; adjusted HR, 0.95). Rates of isolated CNS relapse were also similar with HD-MTX vs no HD-MTX (4.8% vs 6.6%; adjusted HR, 0.81). In propensity score matching (501 pairs), 3-year CNS relapse was 7.4% vs 6.2% (HR, 0.86), and isolated CNS relapse was 5.3% vs 4.5% (HR, 0.83). No benefit was seen in any individual ultra high-risk subgroup. In the matched cohort, 3-year EFS and OS were similar with HD-MTX vs no HD-MTX (73.8% vs 73.7%; p = 0.65 and 82.6% vs 82.7%; p = 0.94). Follow our live feed for more updates: loom.ly/ilKkUIM Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress @mattwilson2287

Thank you to everyone who contributed to this work - it was an honour to present this today at #EHA2026 and to see the publication in JCO, along with an excellent commentary from @DrJFriedberg ascopubs.org/doi/10.1200/JCO…

From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma | Blood | American Society of Hematology ashpublications.org/blood/ar…

My thoughts on new data from EHA. When considered in context of other recently published studies, these results should definitively end the practice of high-dose methotrexate prophylaxis in DLBCL. @JCO_ASCO ascopubs.org/doi/10.1200/JCO…

Does HD-MTX ppx reduce CNS relapse even in ultra-high-risk LBCL? #lymsm - >1900 pts, all CNS-IPI 5-6; testicular, renal/adrenal, breast; ≥3 EN sites - 3-yr CNS relapse: 9.3% (no HD-MTX) v 8.1% (HD-MTX), adjusted HR 1.13 [0.82, 1.57] - no diff in isolated CNS relapse: 5.9% v 5.7% - no diff in relapse rates for any high-risk subtypes - DHL/THL not included End of HD-MTX ppx, although DHL/THL is still a question. cc @tobyeyre82 @mattwilson2287 ascopubs.org/doi/10.1200/JCO…

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

#LymphomaManagement is back for 2026. A leading virtual course for healthcare professionals delivered by @LymphomaAction in collaboration with @OxfordHaem Book now 👉 ow.ly/O6Pk50Z6xpM @tobyeyre82 @graham74GC

A huge effort from all involved! #DLBCL #HDMTX #EHA2026

Humble and inspiring acceptance speech by Dr, Claire Harrison that brought the audience to its feet for a standing ovation. Congratulations on a well deserved @EHA_Hematology Lifetime Achievement Award #EHA26 #EHA2026

‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:  High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients Read the full article: bit.ly/4efwgue

The inimitable Dr Wendy Osborne delivering a fantastic educational on how to optimally manage R/R Large B cell Lymphoma 👏🏾 ⭐️

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study - The Lancet Haematology thelancet.com/journals/lanha…

Important B-cell news!

A pleasure to discuss management of SCNSL - where we have seen significant improvement in outcome but still many challenges & areas of unmet need More clinical & translational research required Thank you for inviting me @TheIACH @Mohty_EBMT & for many excellent questions 👏😊

Current Volume | ASCO Educational Book 2026 ascopubs.org/toc/edbk/curren…

Delighted to have the opportunity to discuss management of #SCNSL Thank you @Mohty_EBMT @TheIACH